How to buy Daré Bioscience stock | $1.28

Daré Bioscience, Inc is a biotechnology business based in the US. Daré Bioscience shares (DARE) are listed on the NASDAQ and all prices are listed in US Dollars. Daré Bioscience employs 16 staff and has a market cap (total outstanding shares value) of 0.00.

Daré Bioscience stock price (NASDAQ: DARE)

Use our graph to track the performance of DARE stocks over time.

Daré Bioscience shares at a glance

• Key figures

Information last updated 2021-07-31.

Latest market close	$1.28
52-week range	$0.94 - $3.01
50-day moving average	$1.55
200-day moving average	$1.72
Wall St. target price	$5.40
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	$-1.05

Buy Daré Bioscience shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

*Signup bonus information updated weekly.

Is it a good time to buy Daré Bioscience stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of Daré Bioscience, Inc by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Daré Bioscience price performance over time

Historical closes compared with the close of $1.28 from 2021-05-28

1 week (2021-07-22)	N/A
1 month (2021-07-02)	-18.99%
3 months (2021-04-30)	-15.23%
6 months (2021-01-29)	N/A

1 year (2020-07-29)	N/A
2 years (2019-07-29)	N/A
3 years (2018-07-29)	N/A
5 years (2016-07-29)	N/A

Daré Bioscience financials

Gross profit TTM	$-83,333
Return on assets TTM	-185.95%
Return on equity TTM	-941.6%
Profit margin	0%
Book value	$0.07
Market capitalisation	$76 million

TTM: trailing 12 months

Shorting Daré Bioscience shares

There are currently 5.3 million Daré Bioscience shares held short by investors – that's known as Daré Bioscience's "short interest". This figure is 126.3% up from 2.3 million last month.

There are a few different ways that this level of interest in shorting Daré Bioscience shares can be evaluated.

Daré Bioscience's "short interest ratio" (SIR)

Daré Bioscience's "short interest ratio" (SIR) is the quantity of Daré Bioscience shares currently shorted divided by the average quantity of Daré Bioscience shares traded daily (recently around 19.5 million). Daré Bioscience's SIR currently stands at 0.27. In other words for every 100,000 Daré Bioscience shares traded daily on the market, roughly 270 shares are currently held short.

However Daré Bioscience's short interest can also be evaluated against the total number of Daré Bioscience shares, or, against the total number of tradable Daré Bioscience shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Daré Bioscience's short interest could be expressed as 0.11% of the outstanding shares (for every 100,000 Daré Bioscience shares in existence, roughly 110 shares are currently held short) or 0.1101% of the tradable shares (for every 100,000 tradable Daré Bioscience shares, roughly 110 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Daré Bioscience.

Find out more about how you can short Daré Bioscience stock.

Daré Bioscience share dividends

We're not expecting Daré Bioscience to pay a dividend over the next 12 months.

Have Daré Bioscience's shares ever split?

Daré Bioscience's shares were split on a 1:10 basis on 19 July 2017. So if you had owned 10 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Daré Bioscience shares – just the quantity. However, indirectly, the new 900% higher share price could have impacted the market appetite for Daré Bioscience shares which in turn could have impacted Daré Bioscience's share price.

Daré Bioscience share price volatility

Over the last 12 months, Daré Bioscience's shares have ranged in value from as little as $0.9447 up to $3.0103. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Daré Bioscience's is 1.5211. This would suggest that Daré Bioscience's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Daré Bioscience overview

Daré Bioscience, Inc. , a clinical-stage biopharmaceutical company, focuses on developing and marketing products for women's health in the United States. The company develops therapies in the areas of contraception, fertility, and sexual and vaginal health. Its products in advanced clinical development include DARE-BV1, a bioadhesive hydrogel formulated with clindamycin phosphate 2% to treat bacterial vaginosis in a single administration that has completed Phase 3 clinical trials; Ovaprene, a hormone-free monthly vaginal contraceptive; and Sildenafil Cream, a cream formulation of sildenafil for topical administration to the vulva and vagina for treatment of female sexual arousal disorder. The company's Phase 1-ready products are DARE-HRT1, a combination of bio-identical estradiol and progesterone intravaginal ring for the treatment of vasomotor symptoms in hormone therapy; DARE-VVA1, a vaginally delivered formulation of tamoxifen to treat vulvar vaginal atrophy in patients with hormone-receptor positive breast cancer; and DARE-FRT1, an intravaginal ring containing bio-identical progesterone for the prevention of preterm birth and broader luteal phase support as part of an in vitro fertilization treatment plan. Its products in pre-clinical stage include DARE-LARC1, a combination product designed to provide reversible contraception; ORB-204 and ORB-214, an injectable formulations of etonogestrel to provide contraception over 6-month and 12-month periods; and DARE-RH1, a non-hormonal contraception for men and women. The company is headquartered in San Diego, California.

Frequently asked questions

What percentage of Daré Bioscience is owned by insiders or institutions?
Currently 5.567% of Daré Bioscience shares are held by insiders and 7.374% by institutions. How many people work for Daré Bioscience?
Latest data suggests 16 work at Daré Bioscience. When does the fiscal year end for Daré Bioscience?
Daré Bioscience's fiscal year ends in December. Where is Daré Bioscience based?
Daré Bioscience's address is: 3655 Nobel Drive, San Diego, CA, United States, 92122 What is Daré Bioscience's ISIN number?
Daré Bioscience's international securities identification number is: US23666P1012 What is Daré Bioscience's CUSIP number?
Daré Bioscience's Committee on Uniform Securities Identification Procedures number is: 15708Q105